Fountain Life vs Human Longevity: Cost, Care and Screening

Fountain Life and Human Longevity offer extensive diagnostics with medical interpretation. Both deserve a comparison of the exact package, ongoing care and the plan after an abnormal result, alongside price. Similar test menus do not mean identical protocols, patient populations or outcomes.

Prices below were checked on October 15, 2026. This is a comparison of public offers and research, not firsthand experience at either clinic or a review of their signed membership agreements.

Current public prices

Fountain Life's shop lists CORE Diagnostics at $10,500 and APEX Membership at $23,500. A public product listing is not confirmation of the complete services, renewal price or outside-care costs for a specific member. Our Fountain Life review examines the cancer-test listing, deposit condition and written confirmations to request.¹⁰¹¹

Human Longevity's homepage lists Executive Health at $8,000 annually, 100+ Care at $12,000 annually and 100+ Concierge at $19,000 annually. Executive Health is described as for people under 65. The site separates a $599 genomics-only offer from the diagnostic and care programs; that lower price is not a full imaging package.¹²

What differs beyond the headline price

Fountain Life describes CORE as a diagnostic experience with physician interpretation, and APEX as an annual program with access to an ongoing team. Confirm the test list and care limits for the package quoted to you; broad brand-level descriptions should not be treated as included services at every tier.¹⁴¹⁵

Human Longevity's current offer distinguishes diagnostic assessment from continuing care: its 100+ Care description adds monitoring and quarterly clinician follow-ups, while 100+ Concierge adds advanced cancer screening and a concierge physician relationship. Ask which specialist services are included rather than infer that every referral or treatment is paid for.¹²

Both may appeal to people who value coordinated testing and can afford the possible next steps. Choosing between them requires a written, comparable service schedule. It is not enough to count scans or biomarkers.

What incidental findings actually mean

An incidental finding is an unexpected abnormality found during imaging. It may be benign, clinically important or initially uncertain. Incidental finding, false positive and overdiagnosis are different concepts. A false positive is a screening result that suggests a condition that is not confirmed. Overdiagnosis detects a real condition that would not have caused symptoms or death; establishing that requires more than a benign follow-up result.

A 2018 systematic review pooled potentially serious findings on brain-and-body MRI at 3.9%, with a very wide 95% confidence interval of 0.4%–27.1%. Limited follow-up data across the review showed serious final diagnoses in 48 of 234 potentially serious findings (20.5%). The remaining findings cannot all be relabeled false positives or overdiagnoses, and those selected follow-up data do not give either clinic's false-positive rate.¹

Protocols, reporting thresholds, age, underlying risk and completeness of follow-up affect results. We therefore do not assume the two companies have identical incidental-finding rates. The broader imaging literature shows considerable variation between modalities and settings.²

Detection and longer life are separate questions

Finding a treatable cancer early can matter greatly to an individual. A detection rate alone cannot establish that a screening program reduces deaths. Earlier diagnosis can lengthen the measured time from diagnosis to death without changing the date of death; overdiagnosis can also make survival statistics look better.

The American College of Radiology's published statement finds insufficient evidence to recommend total-body MRI screening for people without symptoms, risk factors or a relevant family history. That position concerns general screening, not clinically indicated imaging for a symptom or inherited risk.¹³

The possibility of extra investigations is also real: research on reporting potentially serious incidental imaging findings documents subsequent medical assessments and effects on participants. Those research outcomes are not provider-specific estimates for either company.⁶ No evidence cited here establishes a survival advantage of one complete commercial program over the other.

Questions that make the offers comparable

• •What is included? Request the imaging protocol, test list, repeat-test allowances, clinician access and any medical eligibility requirements.
• •What happens after an abnormal result? Establish who explains it, who arranges referrals, how quickly follow-up occurs and which costs you or your insurer may face.
• •What results can you substantiate? Ask for provider-specific detection and follow-up data with denominators and definitions, rather than testimonials or percentages alone.
• •What happens next year? Obtain renewal, cancellation, refund and deposit terms for the exact purchase.

A clean scan does not rule out every disease or replace recommended screening. Likewise, an abnormal result is not automatically evidence that the program saved a life. Continue ordinary primary care and screening appropriate to age and risk.

Our assessment

Fountain Life and Human Longevity should be compared as distinct offers, with different prices and care arrangements. Their public menus establish advertised services; they do not establish equal quality, identical screening harms or a demonstrated lifespan advantage. Start with personal risk and a clinician's assessment of which tests are useful, then compare the written packages and follow-up responsibilities.

For a standalone MRI alternative, see our Prenuvo review. For broader alternatives, see longevity clinics versus lab memberships, concierge versus membership programs, longevity clinic costs and our provider rankings. Our evidence guide explains why a clinical indication and a longevity claim need separate evaluation.